Stay updated on AXA4010 Safety in Sickle Cell Disease Clinical Trial
Sign up to get notified when there's something new on the AXA4010 Safety in Sickle Cell Disease Clinical Trial page.

Latest updates to the AXA4010 Safety in Sickle Cell Disease Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded Revision: v3.4.2 and removed Revision: v3.4.1, indicating a minor version update in the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check18 days agoChange DetectedFooter shows Revision: v3.4.1, replacing v3.4.0.SummaryDifference0.1%

- Check33 days agoChange DetectedMinor UI and editorial text updates were made: a 'Show glossary' option was added; capitalization changes were applied to labels such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and the revision tag was updated to v3.4.0 replacing the prior v3.3.4 and lowercase variants. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check40 days agoChange DetectedThe page’s footer revision label was updated from v3.3.3 to v3.3.4, replacing the previous revision tag. This does not alter the study details or how users interact with the page.SummaryDifference0.1%

- Check69 days agoChange DetectedLocation information has been reorganized under a single 'Locations' section, listing Florida, Georgia, and New Jersey, with previous separate location headings removed. The HHS Vulnerability Disclosure link was removed.SummaryDifference0.5%

- Check91 days agoChange DetectedA minor update shows Revision: v3.3.2 in the page footer, replacing Revision: v3.2.0; there are no changes to core study content such as eligibility criteria or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to AXA4010 Safety in Sickle Cell Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AXA4010 Safety in Sickle Cell Disease Clinical Trial page.